Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2020

01-12-2020 | NSCLC | Original Article

Increased IL-10+CD206+CD14+M2-like macrophages in alveolar lavage fluid of patients with small cell lung cancer

Authors: Xintong Hu, Yue Gu, Songchen Zhao, Shucheng Hua, Yanfang Jiang

Published in: Cancer Immunology, Immunotherapy | Issue 12/2020

Login to get access

Abstract

There are significant differences in pathology, etiology, clinical features, and treatment options between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). However, the differences of macrophage distribution and its associated function between SCLC and NSCLC are not fully investigated. Through methods of flow cytometry and cytometric bead array, we examined the levels of various subtypes of macrophages, monocytes, and regulatory T cells (Tregs) as well as interleukin (IL)-10 in bronchoalveolar lavage fluid (BALF) of patients with SCLC or NSCLC. Our study showed that the frequency of CD14+, CD206+CD14+ and IL-10+CD206+CD14+M2-like macrophages were significantly increased, with simultaneously elevated IL-10 in BALF of SCLC patients, as compared to those in BALF of NSCLC patients. Furthermore, the increased frequency of IL-10+CD206+CD14+M2-like macrophages and elevated level of IL-10 in BALF of SCLC patients were positively correlated with advanced tumor stage, but negatively correlated with their survival time. On the other hand, the level of supernatant IL-10 and frequency of IL-10+CD206+CD14+M2-like macrophages in SCLC patients were positively correlated. The frequency of above mentioned macrophages was also positively correlated with that of Foxp3+CD25+CD4+Tregs. Compared to NSCLC patients, the level of circulating IL-10+CD206+CD14+M2-like monocytes in SCLC patients were significantly increased after chemotherapy. Overall, increased IL-10+CD206+CD14+M2-like macrophages were an important feature of SCLC, rather than NSCLC, and it is associated with development of SCLC.
Appendix
Available only for authorised users
Literature
1.
2.
Murray N, Turrisi AR (2006) A review of first-line treatment for small-cell lung cancer. J Thoraconcol 1(3):270–278
3.
Kurahara Y, Kawaguchi T, Tachibana K, Atagi S, Hayashi S, Kitaichi M, Ou SH, Takada M (2012) Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke. Clin Lung Cancer 13(1):75–79PubMedCrossRef
4.
5.
6.
Ren F, Fan M, Mei J, Wu Y, Liu C, Pu Q, You Z, Liu L (2014) Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. Drug Des Dev Ther 8:1527–1538
7.
Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, Chou CL, Chen HC, Lin SM, Kuo HP (2012) Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer 131(3):E227–E235PubMedCrossRef
8.
Savai R, Schermuly RT, Pullamsetti SS, Schneider M, Greschus S, Ghofrani HA, Traupe H, Grimminger F, Banat GA (2007) A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res 67(11):5443–5453PubMedCrossRef
9.
Uo M, Hisamatsu T, Miyoshi J, Kaito D, Yoneno K, Kitazume MT, Mori M, Sugita A, Koganei K, Matsuoka K, Kanai T, Hibi T (2013) Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation. Gut 62(12):1734–1744PubMedCrossRef
10.
Heeren AM, Kenter GG, Jordanova ES, de Gruijl TD (2015) CD14+ macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread. A new therapeutic lead? Oncoimmunology 4(6):e1009296PubMedPubMedCentralCrossRef
11.
Yuan A, Hsiao YJ, Chen HY, Chen HW, Ho CC, Chen YY, Liu YC, Hong TH, Yu SL, Chen JJ, Yang PC (2015) Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep 5:14273PubMedPubMedCentralCrossRef
12.
Smith PD, Smythies LE, Shen R, Greenwell-Wild T, Gliozzi M, Wahl SM (2011) Intestinal macrophages and response to microbial encroachment. Mucosal Immunol 4(1):31–42PubMedCrossRef
13.
14.
Medeiros LT, Peraçoli JC, Bannwart-Castro CF, Romão M, Weel IC, Golim MA, de Oliveira LG, Kurokawa CS, Medeiros Borges VT, Peraçoli MT (2014) Monocytes from pregnant women with pre-eclampsia are polarized to a M1 phenotype. Am J Reprod Immunol 72(1):5–13PubMedCrossRef
15.
Almatroodi SA, McDonald CF, Darby IA, Pouniotis DS (2016) Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLC. Cancer Microenviron 9(1):1–11PubMedCrossRef
16.
17.
Iriki T, Ohnishi K, Fujiwara Y, Horlad H, Saito Y, Pan C, Ikeda K, Mori T, Suzuki M, Ichiyasu H, Kohrogi H, Takeya M, Komohara Y (2017) The cell–cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation. Lung Cancer 106:22–32PubMedCrossRef
18.
19.
Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM (2010) Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 176(6):2972–2985PubMedPubMedCentralCrossRef
20.
Hsu TI, Wang YC, Hung CY, Yu CH, Su WC, Chang WC, Hung JJ (2016) Positive feedback regulation between IL-10 and EGFR promotes lung cancer formation. Oncotarget 7(15):20840–20854PubMedPubMedCentralCrossRef
21.
Zhu Q, Wu X, Wu Y, Wang X (2016) Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Oncol Rep 36(6):3472–3478PubMedCrossRef
22.
23.
Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, Cullinan DR, Luo J, Bearden AR, Lavine KJ, Yokoyama WM, Hawkins WG, Fields RC, Randolph GJ, DeNardo DG (2017) Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47(2):323–338.e6PubMedPubMedCentralCrossRef
24.
Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z, Gao J (2011) M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 66(11):1879–1886CrossRef
25.
Fu Y, Moore XL, Lee MK, Fernández-Rojo MA, Parat MO, Parton RG, Meikle PJ, Sviridov D, Chin-Dusting JP (2012) Caveolin-1 plays a critical role in the differentiation of monocytes into macrophages. Arterioscler Thromb Vasc Biol 32(9):e117–125PubMedCrossRef
26.
Zhu L, Zhao Q, Yang T, Ding W, Zhao Y (2015) Cellular metabolism and macrophage functional polarization. Int Rev Immunol 34(1):82–100PubMedCrossRef
27.
Muppa P, Parrilha Terra SBS, Sharma A, Mansfield AS, Aubry MC, Bhinge K, Asiedu MK, de Andrade M, Janaki N, Murphy SJ, Nasir A, Van Keulen V, Vasmatzis G, Wigle DA, Yang P, Yi ES, Peikert T, Kosari F (2019) Immune cell infiltration may be a key determinant of long-term survival in small cell lung cancer. J Thorac Oncol 14(7):1286–1295PubMedCrossRef
28.
Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P (2009) Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33(1):118–126PubMedCrossRef
29.
Oser MG, Niederst MJ, Sequist LV, Engelman JA (2015) Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 16(4):e165–172PubMedPubMedCentralCrossRef
30.
Morinaga R, Okamoto I, Furuta K, Kawano Y, Sekijima M, Dote K, Satou T, Nishio K, Fukuoka M, Nakagawa K (2007) Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 58(3):411–413PubMedCrossRef
31.
Bhairavabhotla RK, Verm V, Tongaonkar H, Shastri S, Dinshaw K, Chiplunkar S (2007) Role of IL-10 in immune suppression in cervical cancer. Indian J Biochem Biophys 44(5):350–356PubMed
32.
Koh B, Hufford MM, Sun X, Kaplan MH (2017) Etv5 regulates IL-10 Production in Th cells. J Immunol 198(5):2165–2171PubMedCrossRef
33.
Fioravanti J, Di Lucia P, Magini D, Moalli F, Boni C, Benechet AP, Fumagalli V, Inverso D, Vecchi A, Fiocchi A, Wieland S, Purcell R, Ferrari C, Chisari FV, Guidotti LG, Iannacone M (2017) Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. J Hepatol 67(3):543–548PubMedPubMedCentralCrossRef
34.
Li Y, Rong J, Qin J, He JY, Chen HG, Huang SH (2016) Micro RNA-98 interferes with expression interleukin-10 in peripheral B cells of patients with lung cancer. Sci Rep 6:32754PubMedPubMedCentralCrossRef
35.
Soroosh P, Doherty TA, Duan W, Mehta AK, Choi H, Adams YF, Mikulski Z, Khorram N, Rosenthal P, Broide DH, Croft M (2013) Lungresident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance. J Exp Med 210:775–788PubMedPubMedCentralCrossRef
36.
Duan MC, Han W, Jin PW, Wei YP, Wei Q, Zhang LM, Li JC (2015) Disturbed Th17/Treg balance in patients with non-small cell lung cancer. Inflammation 38(6):2156–2165PubMedCrossRef
37.
38.
39.
Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, Nortier JW, Welters MJ, Kroep JR, van der Burg SH (2013) Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 73(8):2480–2492PubMedCrossRef
40.
Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi A, Afshari JT, Sahebkar A (2018) Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 233(9):6425–6440PubMedCrossRef
41.
Huang YK, Wang M, Sun Y, Di Costanzo N, Mitchell C, Achuthan A, Hamilton JA, Busuttil RA, Boussioutas A (2019) Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry. Nat Commun 10(1):3928PubMedPubMedCentralCrossRef
Metadata
Title
Increased IL-10+CD206+CD14+M2-like macrophages in alveolar lavage fluid of patients with small cell lung cancer
Authors
Xintong Hu
Yue Gu
Songchen Zhao
Shucheng Hua
Yanfang Jiang
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 12/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02639-z

Other articles of this Issue 12/2020

Cancer Immunology, Immunotherapy 12/2020 Go to the issue

Original Article

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Original Article

TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells

Original Article

Factors associated with ocular adverse event after immune checkpoint inhibitor treatment

Research Report

Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis

Original Article

The adjuvant effect of melanin is superior to incomplete Freund’s adjuvant in subunit/peptide vaccines in mice

Original Article

Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits